Benevich S. Eric's Insider Trades & SAST Disclosures
Benevich S. Eric's most recent trade in Atyr Pharma Inc was a trade of 50,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Benevich S. Eric.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Atyr Pharma Inc | Benevich S. Eric | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 42,805 | 42,805 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 8,022 | 8,022 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 2,083 | 44,882 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 2,083 | 4,166 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,961 | 5,885 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,961 | 45,745 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 116.74 per share. | 12 Feb 2025 | 1,098 | 43,784 (0%) | 0% | 116.7 | 128,183 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 116.71 per share. | 12 Feb 2025 | 1,056 | 44,689 (0%) | 0% | 116.7 | 123,245 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2025 | 1,860 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2025 | 1,860 | 43,779 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 118.31 per share. | 08 Feb 2025 | 980 | 42,799 (0%) | 0% | 118.3 | 115,940 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 2,294 | 43,126 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 2,294 | 2,294 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 152.94 per share. | 31 Jan 2025 | 1,207 | 41,919 (0%) | 0% | 152.9 | 184,599 | Common Stock |
| Atyr Pharma Inc | Benevich S. Eric | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 12,587 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 133.36 per share. | 15 Apr 2024 | 12,587 | 40,778 (0%) | 0% | 133.4 | 1,678,660 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.05 per share. | 15 Apr 2024 | 12,587 | 53,365 (0%) | 0% | 81.0 | 1,020,176 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.49 per share. | 15 Apr 2024 | 7,231 | 48,009 (0%) | 0% | 81.5 | 589,254 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 7,231 | 26,292 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 133.36 per share. | 15 Apr 2024 | 7,231 | 40,778 (0%) | 0% | 133.4 | 964,359 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 69,521 | 12,587 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 139.38 per share. | 14 Mar 2024 | 69,521 | 40,778 (0%) | 0% | 139.4 | 9,689,761 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.05 per share. | 14 Mar 2024 | 69,521 | 110,299 (0%) | 0% | 81.0 | 5,634,677 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 14 Mar 2024 | 5,479 | 46,257 (0%) | 0% | 79.0 | 432,951 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 5,479 | 33,881 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 139.38 per share. | 14 Mar 2024 | 5,479 | 40,778 (0%) | 0% | 139.4 | 763,657 | Common Stock |
| Neurocrine Biosciences, Inc. | S. Benevich Eric | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.24 per share. | 28 Feb 2024 | 53,143 | 93,759 (0%) | 0% | 43.2 | 2,297,903 | Common Stock |
| Neurocrine Biosciences, Inc. | Benevich S. Eric | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 53,143 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | S. Eric Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 134.69 per share. | 28 Feb 2024 | 53,143 | 40,616 (0%) | 0% | 134.7 | 7,157,730 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 21,857 | 39,360 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eric Benevich S. | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 134.69 per share. | 28 Feb 2024 | 21,857 | 40,616 (0%) | 0% | 134.7 | 2,943,878 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric Benevich S. | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 28 Feb 2024 | 21,857 | 62,473 (0%) | 0% | 79.0 | 1,727,140 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 39,426 | 39,426 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | S. Benevich Eric | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 7,846 | 7,846 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Benevich Eric S. | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 133.01 per share. | 13 Feb 2024 | 1,098 | 40,616 (0%) | 0% | 133.0 | 146,050 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric Benevich S. | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 142.12 per share. | 06 Feb 2024 | 1,280 | 38,751 (0%) | 0% | 142.1 | 181,910 | Common Stock |
| Neurocrine Biosciences, Inc. | Benevich Eric S. | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 134.19 per share. | 06 Feb 2024 | 980 | 39,631 (0%) | 0% | 134.2 | 131,509 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric Benevich S. | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 140.78 per share. | 31 Jan 2024 | 1,207 | 37,601 (0%) | 0% | 140.8 | 169,927 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 107.40 per share. | 21 Aug 2023 | 1,600 | 36,436 (0%) | 0% | 107.4 | 171,836 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 51,782 | 51,782 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 8,332 | 8,332 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 102.42 per share. | 06 Feb 2023 | 15,360 | 33,501 (0%) | 0% | 102.4 | 1,573,225 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 102.29 per share. | 06 Feb 2023 | 2,030 | 19,705 (0%) | 0% | 102.3 | 207,643 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 105.63 per share. | 06 Feb 2023 | 1,280 | 17,879 (0%) | 0% | 105.6 | 135,201 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 104.12 per share. | 06 Feb 2023 | 980 | 34,381 (0%) | 0% | 104.1 | 102,036 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 109.95 per share. | 31 Jan 2023 | 1,207 | 16,729 (0%) | 0% | 110.0 | 132,710 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.00 per share. | 06 Jan 2023 | 400 | 15,643 (0%) | 0% | 125 | 50,000 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2023 | 400 | 53,143 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.24 per share. | 06 Jan 2023 | 400 | 16,043 (0%) | 0% | 43.2 | 17,296 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.90 per share. | 30 Nov 2022 | 22,162 | 15,643 (0%) | 0% | 125.9 | 2,790,233 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.78 per share. | 30 Nov 2022 | 22,162 | 37,805 (0%) | 0% | 41.8 | 925,928 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2022 | 22,162 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2022 | 20,063 | 53,543 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.90 per share. | 30 Nov 2022 | 20,063 | 15,643 (0%) | 0% | 125.9 | 2,525,966 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.24 per share. | 30 Nov 2022 | 20,063 | 35,706 (0%) | 0% | 43.2 | 867,524 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2022 | 7,775 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.90 per share. | 30 Nov 2022 | 7,775 | 15,643 (0%) | 0% | 125.9 | 978,886 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.99 per share. | 30 Nov 2022 | 7,775 | 23,418 (0%) | 0% | 36.0 | 279,822 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.33 per share. | 08 Nov 2022 | 24,593 | 15,643 (0%) | 0% | 125.3 | 3,082,319 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2022 | 24,593 | 22,262 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.78 per share. | 08 Nov 2022 | 24,593 | 40,236 (0%) | 0% | 41.8 | 1,027,496 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2022 | 100 | 22,162 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.36 per share. | 08 Nov 2022 | 100 | 15,643 (0%) | 0% | 125.4 | 12,536 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.78 per share. | 08 Nov 2022 | 100 | 15,743 (0%) | 0% | 41.8 | 4,178 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2022 | 8,968 | 46,855 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.02 per share. | 02 Nov 2022 | 8,968 | 15,643 (0%) | 0% | 125.0 | 1,121,183 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.78 per share. | 02 Nov 2022 | 8,968 | 24,611 (0%) | 0% | 41.8 | 374,683 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.78 per share. | 02 Nov 2022 | 400 | 16,043 (0%) | 0% | 41.8 | 16,712 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2022 | 400 | 55,823 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.00 per share. | 02 Nov 2022 | 400 | 15,643 (0%) | 0% | 125 | 50,000 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 110.82 per share. | 17 Oct 2022 | 4,960 | 15,643 (0%) | 0% | 110.8 | 549,682 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 80.83 per share. | 07 Feb 2022 | 2,030 | 18,309 (0%) | 0% | 80.8 | 164,081 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 80.78 per share. | 07 Feb 2022 | 1,280 | 19,459 (0%) | 0% | 80.8 | 103,398 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 79.67 per share. | 07 Feb 2022 | 980 | 20,338 (0%) | 0% | 79.7 | 78,073 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 80.68 per share. | 07 Feb 2022 | 809 | 16,483 (0%) | 0% | 80.7 | 65,269 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 62,483 | 62,483 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 9,175 | 9,175 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 89.62 per share. | 16 Aug 2021 | 5,628 | 15,608 (0%) | 0% | 89.6 | 504,395 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 49,049 | 49,049 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 120.03 per share. | 25 Jan 2021 | 3,477 | 17,405 (0%) | 0% | 120.0 | 417,327 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.78 per share. | 25 Jan 2021 | 3,477 | 20,882 (0%) | 0% | 41.8 | 145,269 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2021 | 3,477 | 56,523 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 120.03 per share. | 25 Jan 2021 | 1,600 | 15,805 (0%) | 0% | 120.0 | 192,044 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 120.00 per share. | 25 Jan 2021 | 300 | 15,805 (0%) | 0% | 120 | 36,000 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.78 per share. | 25 Jan 2021 | 300 | 16,105 (0%) | 0% | 41.8 | 12,534 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2021 | 300 | 56,223 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 120.00 per share. | 25 Jan 2021 | 100 | 15,705 (0%) | 0% | 120 | 12,000 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 90.71 per share. | 12 Nov 2020 | 2,257 | 17,405 (0%) | 0% | 90.7 | 204,723 | Common Stock |
| Neurocrine Biosciences, Inc. | Eric S. Benevich | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 118.85 per share. | 05 Aug 2020 | 2,257 | 15,374 (0%) | 0% | 118.9 | 268,254 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges